Elevated serum lipoprotein(a) is significantly associated with angiographic progression of coronary artery disease

Xing Shui PHD¹ | Zheqi Wen MD² | Zefeng Chen PHD¹ | Xujing Xie PHD¹ | Yongxia Wu BSc¹ | Binghan Zheng BSc¹ | Zhen Wu PHD² | Lin Chen MD¹

¹Department of Cardiovascular Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
²Department of Cardiac Care Unit, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Correspondence
Zhen Wu and Lin Chen, No. 600, Tianhe Road, Guangzhou, 510630, China.
Email: chenlin2@mail.sysu.edu.cn and wuzhen@mail.sysu.edu.cn

Abstract

Background: Lipoprotein(a)[Lp(a)] has been considered as an independent risk factor for coronary artery disease (CAD). The present study aimed to evaluate the association between baseline serum Lp(a) and CAD progression determined by angiographic score.

Methods: A total of 814 patients who had undergone two or more coronary computed tomography angiography at least 6 months apart were consecutively enrolled and the coronary severity was determined by the Gensini score system. Patients were stratified into two groups according to Lp(a)>300 mg/L and Lp(a) ≤ 300 mg/L or classified as “progressors” and “non-progressors” based on the Gensini score rate of change per year. The association of continuous Lp(a) and Lp(a)>300 mg/L with CAD progression were respectively assessed by logistic regression analysis. Moreover, further evaluation of those association was performed in subgroups of the study population.

Results: Patients in the “progressors” group had significant higher Lp(a) levels. Furthermore, the multivariate logistic regression analysis showed that elevated Lp(a) (odds ratio [OR]: 1.451, 95% confidence interval [CI]: 1.177–1.789, p<.001) and Lp(a)>300 mg/L (OR:1.642, 95% CI:1.018–2.649, p =.042) were positively associated with CAD progression after adjusting for confounding factors. In addition, those relation seemed to be more prominent in subjects with lower body mass index (OR: 1.880, 95% CI: 1.224–2.888, p for interaction = .060).

Conclusions: Elevated baseline serum Lp(a) is positively and independently associated with angiographic progression of CAD, particularly in participants with relatively low body mass index. Therefore, Lp(a) could be a potent risk factor for CAD progression, assisting in early risk stratification in cardiovascular patients.

Keywords
body mass index, coronary artery disease, Gensini score, lipoprotein(a), progression
1 | INTRODUCTION

Coronary artery disease (CAD) is still a major cause of death worldwide. Despite great advances in its diagnosis, treatment, and prevention, adverse cardiovascular events do not seem to decline on the background of optimal medical therapy. The importance of identifying residual risk and screening the coronary atherosclerotic progression for early prevention remains undisputed.

Lipoprotein[a] (Lp[a]) is composed of a low-density lipoprotein (LDL)-like particle with its apolipoprotein (apo)B100, which covalently bound to a characteristic glycoprotein apolipoprotein[a] (apo[a]) by a disulfide bond. Because of its proatherogenic, proinflammatory and prothrombotic properties, previous studies demonstrated that Lp(a) involved in the pathophysiological process of coronary atherosclerosis. Meanwhile large amounts of evidence from epidemiological studies, mendelian randomization analysis, and genome-wide association studies identified that Lp(a) was an independent risk factor for primary and secondary prevention of CAD. However, the correlation between Lp(a) and coronary atherosclerosis progression remains controversial. Previously, two study groups assessed the predictive utility of Lp(a) in coronary atherosclerosis progression by intravascular ultrasound, opposite results were obtained. With the development of computed tomography technology, coronary computed tomography angiography (CTA) has been widely used for non-invasive assessment of coronary atherosclerosis at outpatient department. Compared with invasive coronary angiography, the predictive value of coronary artery stenosis by coronary CTA had high sensitivity and specificity. Moreover, coronary CTA was more available and convenient for clinical application than invasive intravascular ultrasound.

Hence, in the present study, we aimed to analyze the association between baseline Lp(a) levels and angiographic progression of CAD by Gensini score system according to the results of coronary CTA in suspected CAD patients at outpatient department.

2 | METHODS

2.1 | Study population

This was a retrospective longitudinal study conducted at the Third Affiliated Hospital, Sun Yat-sen University between April 2008 and May 2016. The study subjects comprised of 1350 cardiovascular patients who underwent twice-coronary CTA at least 6 months apart at outpatient department were enrolled. Patients initially received coronary CTA examination due to angina-like symptoms, an abnormal ECG (including abnormal Q wave, ST-T changes, or new complete left bundle branch block), an abnormal echocardiogram, positive treadmill exercise test or elevated cardiovascular risk. Based on the severity of angina-like symptoms or coronary CTA images, some of them were admitted for further treatment. Among them, 421 patients receiving percutaneous coronary intervention or coronary bypass surgery were excluded. In addition, other exclusion criteria included patients with malignancy, estimated glomerular filtration rate (eGFR)<60 ml/min/1.73m², acute inflammatory disease, 0.5<Gensini score rate of change per year<1, or missing data. Eventually, 814 patients were analyzed. This study was in line with the medical ethics standards of the 1975 Declaration of Helsinki and approved by the Ethics Committee of The Third Affiliated Hospital, Sun Yat-sen University. Written informed consent was obtained from each patient.

2.2 | Clinical and laboratory parameters

Clinical parameters including age, sex, height, weight, systolic and diastolic blood pressure (DBP), heart rate, comorbidities, and medications were collected at outpatient or admission. Body mass index (BMI) was calculated from weight in kg divided by height in m². Hypertension (HTN) was defined as systolic blood pressure (SBP) ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mmHg or currently using anti-hypertensive agents. Diabetes (DM) was defined as fasting serum glucose ≥ 7.0 mmol/L or random serum glucose ≥ 11.1 mmol/L or the 2-h serum glucose of the oral glucose tolerance test ≥ 11.1 mmol/L or using anti-diabetic medication. Smoking status was defined as a person who smoked at the time of initial coronary CTA or who had quit smoking within the year before initial coronary CTA. Obstructive CAD was defined as coronary stenosis of 50% or more in the epicardial coronary artery determined by initial coronary CTA.

Blood samples were obtained from each patient in the fasting state at outpatient or after admission and then tested in laboratory medicine as soon as possible. The serum lipid profiles including total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apoA1, apoB100, and Lp(a) were determined by automatic biochemical analyzer (Hitachi 7600, Tokyo, Japan). In addition, in detail, TC and TG were measured with enzyme colorimetry method, while LDL-C and HDL-C were determined by the direct method. ApoA1 and apoB100 were measured with immunoturbidimetry method. The serum concentration of Lp(a) was analyzed using latex immunoturbidimetry method. Due to racial differences, the optimal risk cutoffs for cardiovascular disease were still not clearly determined. The European Atherosclerosis Society proposed Lp(a) <50 mg/dl as the appropriate cutoffs, while China and the United States recommended Lp(a) <30 mg/dl as a desirable level. According to Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adult, 300 mg/L was selected as a cutoff value in our center. The normal range was 0-300 mg/L. Non-HDL-C levels were calculated as TC minus HDL-C levels.

2.3 | Coronary computed tomography angiography and Gensini score assessment

The 320-slice coronary CTA was performed by a predefined standard operating procedure as previously described. Before coronary CTA examination, oral metoprolol tablets (50–100mm Hg, Astrazeneca) were given to patients with a resting heart rate >70 bpm. All patients were in the supine position and held their breath during the imaging
Isovue-370 (50–100 ml, Bracco Diagnostics, Guangzhou, China) was injected intravenously at a flow rate of 6.0 ml/s, followed by a 20 ml saline flush at a flow rate of 4.0 ml/s. 320-slice coronary CTA was performed with 0.5-mm detector element, 350 ms of gantry rotation time, and up to 16 cm of coverage in Z direction. Tube voltages were set at 100–135 kV and the maximal tube currents were set at 400–580 mA.

All coronary CTA images were reconstructed and analyzed using a dedicated workstation (VitreafX Version 2.1, TOSHIBA) by experienced radiologists, which in accordance with the Society of Cardiovascular Computed Tomography guidelines. The severity of coronary artery was assessed by angiographic scoring system: the Gensini score system, which were calculated by three experienced interventional cardiologists. Based on the degree of luminal narrowing, severity scores indicated angiographic stenosis of coronary artery segment were 1, 2, 4, 8, 16, and 32 for 0%–25%, 26%–50%, 51%–75%, 76%–90%, 91%–99%, and 100%, respectively. Given the variation in time during the coronary CTAs, the Gensini score rate of change per year was used to define angiographic CAD progression as detailed elsewhere. In brief, subjects were arbitrarily categorized as “progressors” and “non-progressors” based on a Gensini score rate of change of >1 or ≤0.5 points/year, respectively. Subject with a Gensini score rate of change between 0.5< and 1 points/year were excluded as “gray area” in the present study.

2.4 | Statistical analysis

All statistical analyses were performed using SPSS 25.0 software (IBM Corporation, Armonk, NY) for Windows. Continuous variables were shown as mean ± SD, or median with interquartile range, as appropriate. Student t test or Mann–Whitney U-test was used to determine the differences in continuous variables between groups. Categorical variables were expressed as frequencies with percentage and analyzed by Chi square tests. Logistic regression analyses were conducted to explore the association between baseline Lp(a) and angiographic progression of CAD. Firstly, univariate logistic regression analyses were performed. Baseline Lp(a) was analyzed as a continuous variable or a categorical variable with a cutoff value as 300 mg/L according to Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adult, respectively. Since the distribution of baseline Lp(a) showed positive skewing, it was logarithmically transformed when analyzed as a continuous variable. Therefore, the results were showed by odds ratio(OR) per log-unit increase. Secondly, Multivariate logistic regression analyses were performed in three different models to adjust potential confounders. Covariates selection of multivariate logistic regression models was done by stepwise forward method and threshold values for F-to-enter and F-to-remove were 0.05 and 0.1, respectively. Model 1 was adjusted for age and gender. In Model 2, it was additionally adjusted for BMI, smoking status, history of HTN, DM, and initially obstructive CAD. In Model 3, we added HbA1c, fasting plasma glucose(FPG), HDL-C, non-HDL, LDL-C, creatinine, uric acid (UA), and white cell counts (WBC) as confounding factors to assess the independent relation between Lp(a) and CAD progression. Thirdly, subgroup analyses were conducted after categorizing the patients according to sex, age, BMI, smoking status, history of HTN, DM, and initially obstructive CAD. In subgroup analyses, OR was obtained by log-transformed continuous variable of Lp(a) after adjustment of covariates in Model 3. p-value of .05 was defined as statistically significant.
3 | RESULTS

3.1 | Baseline characteristics of subjects

A total of 814 eligible patients were entered into this study. The baseline serum Lp(a) values ranged from 3.00 to 1575.00 mg/L (median = 133.65 mg/L, interquartile range = 68.10–254.75 mg/L). Table 1 shows the baseline clinical characteristics of the study subjects. Patients were stratified into two groups according to Lp(a)>300 mg/L and Lp(a) ≤ 300 mg/L. Several baseline clinical and biochemical characteristics were compared between groups. Serum TC, HDL-C, Non-HDL-C, and LDL-C levels increased in the higher Lp(a) group. However, no significant difference was observed in demographic characteristics, clinical comorbidities, medications, as well as serum levels of TG, ApoA1, ApoB100, FPG, HbA1c, creatinine, eGFR, UA, and WBC.

3.2 | Impact of clinical variables on coronary artery disease progression

Subjects were divided into two groups on the basis of the presence of angiographic CAD progression(a Gensini rate of change of >1 or ≤ 0.5

| Variables | Lp(a) ≤300 mg/L(n = 646) | Lp(a) >300 mg/L(n = 168) | p |
|-----------|--------------------------|--------------------------|---|
| Age, year | 63.02 ± 10.82 | 63.99 ± 10.39 | .297 |
| Male, n(%) | 340 (52.6) | 84 (50.0) | .543 |
| BMI, kg/m² | 24.61 ± 3.10 | 24.11 ± 2.81 | .058 |
| Smoking, n(%) | 175 (30.5) | 38 (26.6) | .359 |
| Hypertension, n(%) | 426 (66.3) | 112 (66.7) | .919 |
| Diabetes, n(%) | 261 (40.5) | 62 (36.9) | .401 |
| O-CAD, n(%) | 226 (35.0) | 51 (30.4) | .259 |
| SBP, mm Hg | 140.72 ± 21.70 | 141.62 ± 19.23 | .700 |
| DBP, mm Hg | 78.55 ± 12.07 | 76.64 ± 10.90 | .164 |
| HR, bpm | 76.21 ± 12.21 | 77.95 ± 11.09 | .187 |

**Laboratory tests**

| TC, mmol/L | 4.87 ± 1.16 | 5.18 ± 1.19 | .002 * |
| TG, mmol/L | 1.96 ± 1.82 | 1.75 ± 1.09 | .175 |
| HDL-C, mmol/L | 1.16 ± 0.30 | 1.23 ± 0.35 | .004 * |
| LDL-C, mmol/L | 3.00 ± 0.94 | 3.32 ± 1.01 | <.001 * |
| Non-HDL, mmol/L | 3.72 ± 1.11 | 3.95 ± 1.09 | .016 * |
| ApoA1, g/L | 1.35 ± 0.27 | 1.36 ± 0.26 | .692 |
| ApoB100, g/L | 1.04 ± 0.37 | 1.10 ± 0.36 | .088 |
| FPG, mmol/L | 6.24 ± 3.01 | 6.36 ± 2.67 | .657 |
| HbA1c, (%) | 6.63 ± 1.64 | 6.62 ± 1.70 | .955 |
| Creatinine, umol/L | 76.15 ± 20.20 | 75.36 ± 19.55 | .651 |
| eGFR, ml/min/1.73m² | 85.11 ± 47.58 | 83.89 ± 44.64 | .765 |
| UA, umol/L | 371.86 ± 111.41 | 367.62 ± 111.94 | .662 |
| WBC, ×10E9/L | 6.87 ± 1.74 | 6.85 ± 1.65 | .906 |

**Medication**

| Anti-platelet drug, n(%) | 545 (84.4) | 150 (89.3) | .108 |
| Statins, n(%) | 548 (84.8) | 144 (85.7) | .775 |
| ACEI/ARB, n(%) | 418 (64.7) | 116 (69.0) | .291 |
| β-blocker, n(%) | 354 (54.8) | 100 (59.5) | .272 |
| OAD, n(%) | 218 (33.7) | 51 (30.4) | .405 |
| Insulin, n(%) | 96 (14.9) | 28 (16.7) | .562 |

Abbreviations: ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; LDL-C, low-density lipoprotein cholesterol; OAD, oral anti-diabetic drugs; O-CAD, initially obstructive coronary artery disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; UA, uric acid; WBC, white cell counts.

*p<.05.
Table 2: Baseline and follow-up Gensini score related parameters according to serum Lp(a) levels

| Variables                  | Total (n = 814) | Lp(a) ≤ 300 mg/L (n = 646) | Lp(a) >300 mg/L (n = 168) | p   |
|---------------------------|----------------|-----------------------------|---------------------------|-----|
| Initial Gensini score     | 7.23 ± 11.62   | 7.25 ± 11.92                | 7.13 ± 10.38              | .908|
| Changes in Gensini score  | 2.31 ± 9.44    | 1.95 ± 8.97                 | 3.69 ± 11.00              | .033*|
| Observation time, year    | 2.42 (1.48,3.68)| 2.40 (1.50,3.65)            | 2.53 (1.30,3.89)          | .891|
| Progression, n(%)         | 258 (31.7)     | 192 (29.7)                   | 66 (39.3)                 | .018*|

*p<0.05.

Table 3: Multivariate logistic regression analysis for CAD progression

| OR   | 95% CI | p   |
|------|--------|-----|
| Unadjusted Model            |        |     |
| Continuous Lp(a)            | 1.287  | 1.101–1.503 | .002* |
| Lp(a) >300 mg/L             | 1.530  | 1.075–2.177 | .018* |
| Adjusted Model 1            |        |     |
| Continuous Lp(a)            | 1.284  | 1.095–1.506 | .002* |
| Lp(a) >300 mg/L             | 1.530  | 1.066–2.195 | .021* |
| Adjusted Model 2            |        |     |
| Continuous Lp(a)            | 1.330  | 1.120–1.580 | .001* |
| Lp(a) >300 mg/L             | 1.654  | 1.112–2.461 | .013* |
| Adjusted Model 3            |        |     |
| Continuous Lp(a)            | 1.451  | 1.177–1.789 | <.001* |
| Lp(a) >300 mg/L             | 1.642  | 1.018–2.649 | .042* |

Note: Results of continuous Lp(a) were represented by OR per log-unit increase. Model 1 was adjusted for age and sex. Model 2, further adjusted for BMI, history of HTN, DM, O-CAD, and smoking status. Model 3, further adjusted for HbA1c, FPG, non-HDL, LDL-C, creatinine, UA, and WBC. Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; FPG, fasting plasma glucose; LDL-C, high-density lipoprotein cholesterol; HDL-C, low-density lipoprotein cholesterol; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; O-CAD, initially obstructive coronary artery disease; OR, odds ratio; UA, uric acid; WBC, white cell counts. *p<0.05.

3.3 Gensini score at baseline and follow-up according to baseline serum Lp(a) levels

Table 2 summarizes baseline and follow-up changes in Gensini score. The initial Gensini score of all subjects was 7.23 ± 11.62 based on a per-patients analysis. The absolute change of Gensini score was 2.31 ± 9.44 after a median follow-up period of 2.42 (IQR: 1.48–3.68) year. When the Gensini score rate of change per year was used to define CAD progression, there were 258 (31.7%) patients with CAD progression (a Gensini rate of change of ≥1 points/year), while the other 556 (68.3%) patients did not have significant progression (a Gensini rate of change of ≤0.5 points/year). Moreover, the incidence of CAD progression was statistically higher in patients with Lp(a) >300 mg/L (39.3% vs. 29.7%, p = .018).

3.4 Association of baseline Lp(a) levels with coronary artery disease progression

As a log-transformed continuous variable, univariate logistic regression analysis demonstrated that increasing Lp(a) level was positively associated with CAD progression (OR 1.287, 95% CI 1.101–1.503 p = .002). In the multivariate analysis adjusting for age and sex in Model 1 showed the odds ratio for progression was 1.284 (95% CI 1.095–1.506 p = .002). In Model 2, results seemed to enhanced these correlation after adjustment of clinical comorbidities, smoking status and BMI (OR 1.330, 95% CI 1.120–1.580; p = .001). In Model 3 including other serum lipids, HbA1c, FPG, creatinine, UA and WBC as covariates together, increasing Lp(a) level was still positively correlated to CAD progression (OR 1.451, 95% CI 1.177–1.789; p<.001).

The association between baseline Lp(a) and CAD progression was also explored by categorizing the Lp(a) with a cutoff value of 300 mg/L. In unadjusted multivariable logistic regression analysis revealed that the odds ratio for CAD progression increased in patients with higher Lp(a) group (OR 1.530, 95% CI 1.075–2.177; p = .018). This positive correlation remained statistically significant after adjusting for age, sex, BMI, history of HTN, DM, initially obstructive CAD, smoking status, HbA1c, FPG, non-HDL, LDL-C, creatinine, UA, and WBC (OR 1.642, 95% CI 1.018–2.649; p = .042). Results of logistic regression analyses are summarized in Table 3.

3.5 Subgroup analysis for the relation of Lp(a) with CAD progression

Further assessment of the association between baseline serum Lp(a) and CAD progression was performed in various subgroups of the study population(Figure 2). After adjustment of several covariates in Model 3, subgroup analysis indicated that subjects with aged ≥60 years, with lower BMI, with male gender, with initially obstructive...
CAD had higher odds ratios than those without these risk factors. Meanwhile, subjects with DM, with HTN, and with smoking status had lower odds ratios. However, the association of baseline Lp(a) and CAD progression seemed to be more prominent in subjects with lower BMI (OR [95% CI] BMI < 24 kg/m^2 1.880 [1.224–2.888] vs. BMI ≥ 24 kg/m^2 0.832 [0.469–1.476], p for interaction = 0.060).

### DISCUSSION

In the present study, our results demonstrated that elevated baseline serum Lp(a) was positively associated with angiographic progression of coronary artery disease, particularly in patients with relatively lower BMI, independent of traditional cardiovascular risk factors, including age, sex, BMI, history of HTN, DM, initially obstructive CAD, smoking status, HbA1c, FPG, non-HDL, HDL-C, LDL-C, creatinine, UA and WBC. Our findings contribute to a growing body of literature supporting the hypothesis that Lp(a) is correlated with progression of CAD.

Many previous studies have described the correlation between Lp(a) and coronary atherosclerosis progression using invasive imaging methods. In one study performed in 76 patients with acute coronary syndrome (ACS) who underwent intravascular ultrasound (IVUS) at baseline and at 10-month follow-up after percutaneous coronary intervention, the results showed that patients with serum levels of Lp(a) > 20 mg/dl had slight plaque progression despite of statin therapy, suggesting Lp(a) levels could be an alternative predictor of further plaque progression.10 Similarly, Hartmann et al. reported that Lp(a) was positively related to plaque progression in the left main coronary artery by serial IVUS examinations.18 Chetan et al. also demonstrated that Lp(a) was positively and independently correlated with increased percent atheroma volume by using IVUS examination.19 Furthermore, a meta-analysis with nine cohort studies including 1834 patients was conducted to evaluate the association between the baseline Lp(a) levels and the restenosis after successful coronary stenting. The results indicated that elevated baseline Lp(a) levels were positively associated with increased risk of in-stent restenosis after successful coronary stent implantation.20 Moreover, Maya et al. found CAD patients with elevated LP(a) levels (>50 mg/dl) undergoing specific Lp(a) apheresis for 18 months produced regression of coronary atherosclerosis on the background of optimal medical therapy, suggesting Lp(a) could be a novel predictive and therapeutic biomarker for coronary atherosclerosis burden.21 In the present study, we analyzed the association between baseline serum levels of Lp(a) and progression of CAD by non-invasive coronary CTA, which was considered as convenient tool and widely used in clinic. The Gensini score system was utilized to evaluate the severity of coronary lesions. According to the definition of progression described previously by Riyaz et al.,17 we revealed that angiographic progression of CAD positively associated not only with continuous serum levels of Lp(a) but also with Lp(a) > 300 mg/L before and after adjustment of conventional risk factors, which was consistent with previous studies.

Conversely, Puri et al. found no evidence of a correlation of Lp(a) with coronary atheroma progression rate during 2 years high-intensity statin therapy in sub-analysis of the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) trial.9 Their findings showed that neither baseline nor on-treatment Lp(a) levels in patients with CAD under high-intensive statin treatment had effect on changes in coronary disease.

### Table 1

| Subgroup     | N   | OR (95% CI) | P value | P for interaction |
|--------------|-----|-------------|---------|-------------------|
| Sex          |     |             |         |                   |
| Male         | 424 | 1.795 [1.303–2.474] | <0.001  |                    |
| Female       | 390 | 1.217 [0.904–1.638] | 0.195   |                    |
| Age          |     |             | 0.067   |                    |
| <60 years    | 287 | 1.101 [0.752–1.612] | 0.622   |                    |
| ≥60 years    | 527 | 1.696 [1.302–2.210] | <0.001  |                    |
| BMI          |     |             | 0.060   |                    |
| <24          | 288 | 1.880 [1.224–2.888] | 0.004   |                    |
| 24–28        | 430 | 1.487 [1.111–1.992] | 0.008   |                    |
| >28          | 96  | 0.832 [0.469–1.476] | 0.530   |                    |
| Diabetes     |     |             | 0.466   |                    |
| Yes          | 323 | 1.358 [1.019–1.808] | 0.037   |                    |
| No           | 490 | 1.609 [1.154–2.244] | 0.005   |                    |
| Hypertension |     |             | 0.757   |                    |
| Yes          | 538 | 1.427 [1.120–1.817] | 0.004   |                    |
| No           | 276 | 1.548 [0.941–2.547] | 0.085   |                    |
| Obstructive CAD | |             | 0.092   |                    |
| Yes          | 277 | 2.088 [1.385–3.147] | <0.001  |                    |
| No           | 537 | 1.253 [0.967–1.619] | 0.088   |                    |
| Smoking      |     |             | 0.277   |                    |
| Yes          | 242 | 1.234 [0.823–1.850] | 0.308   |                    |
| No           | 572 | 1.577 [1.218–2.042] | 0.001   |                    |
atheroma volume. One possible explanation for the discrepancy between our study and the SATURN trial was racial difference, as 96% were Caucasian in SATURN trial. Previous study included 6086 patients with first myocardial infarction were stratified by race and adjusted for age and sex. The study found that increased Lp(a) levels were significantly associated with increased MI risk, particularly in South Asian and Latin American populations. Until now, racial difference in the correlation between Lp(a) and increased ASCVD risk remains controversial. Meanwhile, differences in the enrolled patients could also account for the discrepancy. The present study group comprised patients with cardiovascular risk in both of primary and secondary prevention populations at outpatient department, while the SATURN trial screened subjects with stable CAD. Most of patients received moderate-intensive statin therapy in our study, however, patients were given high-intensive statin therapy in SATURN trial. The follow-up LDL values were much lower in SATURN trial (rosuvastatin group 60.5 ± 25.9 mg/dl, atorvastatin group 67.2 ± 22.6 mg/dl), compared with those in our study (follow-up total LDL-C 105.2 ± 37.5 mg/dl). Our results showed that patients in “progressors” group had higher serum levels of Lp(a) than those in “non-progressors” group despite of comparable follow-up LDL-C levels (105.5 ± 39.0 vs. 105.2 ± 36.7, p = 0.871), implying the potential predictive value of Lp(a) on the basis of comparable LDL-C levels. Interestingly, a meta-analysis with 11 studies including 18 979 patients performed to assess the prognostic value of Lp(a), the authors confirmed that the correlation between Lp(a) and cardiovascular events may be attenuated in patients with lower levels of LDL-C.

Furthermore, it was found that the prognostic utility of Lp(a) as a marker of risk in the setting of primary and secondary prevention was apparently only in the population with higher cholesterol levels. However, a single-center cross-sectional study was recently conducted to investigate the association between Lp(a) and coronary atherosclerotic lesion using Gensini score, Li et al. found the association was influenced by LDL-C levels. They revealed that Lp(a) was the risk factors of coronary atherosclerotic heart disease in patients with LDL-C<100 mg/dl. Therefore, the evaluation of Lp(a) in patients with well controlled cholesterol remained to be further studied.

Another interesting finding of the present study was that the association of baseline Lp(a) and CAD progression seemed to be more prominent in subjects with relatively lower BMI, even after controlling for conventional covariates. In prior studies, obesity has been considered as an independent risk factor for CAD, as well as increased rates of adverse cardiovascular events. Current guidelines recommend weight control to be a fundamental lifestyle changes strategy in management of CAD. Previously, Troy et al. conducted a prospective multicenter observational study to confirm that increased BMI had a strong and consistent relationship with the prevalence, extent, and severity of CAD. Afterward, Cho et al. analyzed the association between obesity type and CAD in stable symptomatic postmenopausal women. The authors revealed that central obesity but not overall obesity was related to obstructive CAD. As we know obesity usually accompanies with several clinical comorbidities, such as HTN, DM, and hyperlipidemia, which may categorize to the high risk individuals. Nowadays, many guidelines recommend to screen the Lp(a) level mostly in high-risk individuals. However, the present study showed the association of baseline Lp(a) and CAD progression was more prominent in patients with relatively lower BMI rather than obesity, one possible explanation was that Lp(a) may play a significant role as an overlooked “residual risk factor,” which implying the importance of routine Lp(a) measurement to assist in early risk stratification in seemingly normal-sized populations. Further studies are needed to confirm the relationship and reveal the underlying mechanism.

In the present study, there were several limitations. First, due to the variable numbers of the KIV type2 domains, method we used in the present study may be influenced by the apo(a) sizes. The results of Lp(a) levels may be overestimated or underestimated and may cause inaccurate evaluation of a patient’s risk for CAD progression. Second, since this was a retrospective, longitudinal study conducted at a single-center, residual confounders are hard to avoid. For example, diet, excise, alcohol consumption patterns, and genetic background were not monitored during the study, which was variable. Third, this study only enrolled patients who took repeated coronary CTA for suspected CAD, which could lead to a selection bias. Fourth, only quantitative CTA analysis and angiographic score were performed due to noninvasive and convenience for clinical application, qualitative analysis of coronary plaques was unavailable. Fifth, as Lp(a) was genetically determined by LPA gene, with little influence from lifestyle interventions, therefore, Lp(a) levels did not fluctuate significantly during the whole life. In the present study, we mainly aimed to analyze the correlation between baseline Lp(a) and coronary artery progression. In addition, 85% subjects received statins treatment in our study. Currently, statins effect on Lp(a) metabolism was still not well understood, resulting in controversial results by different statins. Whether changes in Lp(a) levels over time could affect the result will need additional study. Thus, further studies are required in multicenter and larger populations to confirm our findings, especially therapeutic strategies of Antisense oligonucleotide (ASO) technology.

5 | CONCLUSION

In conclusion, the current study found that baseline serum Lp(a) concentration was significantly associated with angiographic progression of CAD, particularly in those with relatively low BMI. Therefore, Lp(a) could be a potent risk factor for progression of CAD, assisting in early risk stratification in cardiovascular patients. Further studies will clearly be required to confirm our findings.

ACKNOWLEDGMENTS

The authors express sincere thanks to Dr. Zhuoshan Huang for his help in statistics.

CONFLICT OF INTEREST

No conflict of interest was declared.
AUTHOR CONTRIBUTIONS
Conceived and designed the study: Lin Chen and Zhen Wu; clinical data acquisition: Binghan Zheng and Yongxia Wu; data analysis: Xujing Xie, Zefeng Chen and Zhen Wu; statistical analysis: Xing Shui and Zheqi Wen; Manuscript drafting: Xing Shui, Zheqi Wen and Zefeng Chen; Each author contributed important intellectual content during manuscript writing or revision.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Lin Chen https://orcid.org/0000-0003-1988-3483

REFERENCES
1. Omland T, White HD. State of the art: blood biomarkers for risk stratification in patients with stable ischemic heart disease. Clin Chem. 2017;63(1):165-176.
2. Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein (a): an update of a marker on a residual risk and associated clinical manifestations. Am J Cardiol. 2020;126:94-102.
3. Rogier A, van Dijk FK, Ravandi A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res. 2012;53(12):2773-2790.
4. Schnitzler JG, Hoogeveen RM, Ali L, et al. Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. Circ Res. 2020;126(10):1346-1359.
5. Rawther T, Tabet F, Biology, pathophysiology and current therapies that affect lipoprotein(a) levels. J Mol Cell Cardiol. 2019;131:1-11.
6. Ong KL, McClelland RL, Allison MA, et al. Lipoprotein(a) and coronary artery calcification: prospective study assessing interactions with other risk factors. Metabolism. 2021;116:154706.
7. Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619-627.
8. Pia R, Kamstrup AT-H, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339.
9. Puri R, Ballantyne CM, Hoogeveen RC, et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN. Atherosclerosis. 2017 Aug;264:137-144.
10. Matsushita K, Hibi K, Komura N, et al. Impact of serum lipoprotein(a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a Yokohamaacs substudy. J Cardiol. 2020 Jul;76(1):66-72.
11. Matthew J, Budoff DD, Jolls JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (assessment by coronary computed tomographic angiography of individuals undergoing invasive coronary angiography) trial. J Am Coll Cardiol. 2008;52(1):1724-1732.
12. Tsimikas S, Fazio S, Ferdinand KC, et al. NHBLI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177-192.
13. Joint Committee for the Revision of guidelines for the prevention and treatment of dyslipidemia in Chinese adults. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (2016 revision edition). Chin Circ J. 2016;31(10):937-953.
14. Li S, Tang X, Luo Y, et al. Impact of long-term glucose variability on coronary atherosclerosis progression in patients with type 2 diabetes: a 2.3 year follow-up study. Cardiovasc Diabetol. 2020;19(1):146.
15. Abbara S, Blanke P, Maroules CD, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: a report of the society of cardiovascular computed tomography guidelines committee: endorsed by the north American Society for Cardiovascular Imaging (NASCI). J Cardiovasc Comput Tomogr. 2016;10(6):435-449.
16. Zhou B-Y, Sun D, Wang C, et al. Plasma lipoprotein(a) concentration is associated with the coronary severity but not with events in stable coronary artery disease patients: a Chinese cohort study. Heart Lung Circ. 2019;28(7):1009-1017.
17. Riyaz S, Patel SS, Neeland UJ, et al. The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J. 2010;31(24):3017-3023.
18. Hartmann M, von Birgelen C, Mintz GS, et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol. 2006;48(3):446-452.
19. Huded CP, Shah NP, Puri R, et al. Association of Serum Lipoprotein(a) levels and coronary atheroma volume by intravascular ultrasound. J Am Heart Assoc. 2020;9(23):e018023.
20. Qin S-y, Liu J, Jiang H-x, et al. Association between baseline lipoprotein(a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies. Atherosclerosis. 2013;227(2):360-366.
21. Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14(1):93-99.
22. Paré G, Čaku A, McQueen M, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139(12):1472-1482.
23. Steffen BT, Thanassoulis G, Duprez D, et al. Race-based differences in lipoprotein(a)-associated risk of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(3):523-529.
24. Liu Y, Ma H, Zhu Q, et al. A genome-wide association study on lipoprotein(a) levels and coronary artery disease severity in a Chinese population. J Lipid Res. 2019;60(8):1440-1448.
25. O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014;63(5):520-527.
26. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA. 2009;302(4):412-423. https://doi.org/10.1001/jama.2009.1063.
27. Li C, Chen Q, Zhang M, et al. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL. BMC Cardiovasc Disord. 2021;21(1):41.
28. Pedersen LR, Olsen RH, Anholm C, et al. Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial. Cardiovasc Diabetol. 2019;18(1):127.
29. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
30. Labounty TM, Gomez MJ, Achenbach S, et al. Body mass index and the prevalence, severity, and risk of coronary artery disease: an international multicentre study of 13,874 patients. Eur Heart J Cardiovasc Imaging. 2013;14(5):456-463.
31. Cho JH, Kim H-L, Kim M-A, et al. Association between obesity type and obstructive coronary artery disease in stable symptomatic postmenopausal women: data from the KoRean wOmen’S chest pain rEgistry (KoROSE). Menopause. 2019;26(11):1272-1276.

32. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.

33. Gencer B, Kronenberg F, Stroes ES, et al. Lipoprotein(a): the revenant. Eur Heart J. 2017;38(20):1553-1560.

34. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692-711.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Shui X, Wen Z, Chen Z, et al. Elevated serum lipoprotein(a) is significantly associated with angiographic progression of coronary artery disease. Clin Cardiol. 2021;44(11):1551-1559. doi:10.1002/clc.23718